BBA
EWTX icon

Baker Bros. Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Baker Bros. Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$207M Hold
6,575,940
– – 1.19% 15
2025
Q4 		$163M Sell
6,575,940
-730,000
-10% -$14.7M 0.96% 15
2025
Q3 		$119M Hold
7,305,940
– – 0.86% 14
2025
Q2 		$95.8M Buy
7,305,940
+1,150,000
+19% +$16.6M 0.93% 13
2025
Q1 		$135M Hold
6,155,940
– – 1.5% 11
2024
Q4 		$164M Buy
6,155,940
+315,881
+5% +$10.1M 1.76% 11
2024
Q3 		$156M Hold
5,840,059
– – 1.62% 11
2024
Q2 		$105M Hold
5,840,059
– – 1.34% 11
2024
Q1 		$107M Buy
5,840,059
+2,727,273
+88% +$43.3M 1.34% 10
2023
Q4 		$34.1M Buy
3,112,786
+2,063,087
+197% +$14.5M 0.39% 30
2023
Q3 		$6.01M Buy
1,049,699
+549,699
+110% +$3.74M 0.03% 63
2023
Q2 		$3.88M Hold
500,000
– – 0.02% 78
2023
Q1 		$3.33M Hold
500,000
– – 0.02% 81
2022
Q4 		$4.47M Hold
500,000
– – 0.03% 79
2022
Q3 		$4.92M Hold
500,000
– – 0.03% 81
2022
Q2 		$3.98M Hold
500,000
– – 0.02% 83
2022
Q1 		$4.85M Hold
500,000
– – 0.03% 85
2021
Q4 		$7.64M Hold
500,000
– – 0.04% 83
2021
Q3 		$8.3M Hold
500,000
– – 0.04% 81
2021
Q2 		$10.7M Hold
500,000
– – 0.05% 75
2021
Q1 		$16.3M Buy
+500,000
New +$16.2M 0.07% 63

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baker Bros. Advisors's EWTX Position: Q1 2026 in Review

Baker Bros. Advisors held its Edgewise Therapeutics (EWTX) position steady in Q1 2026 at 6,575,940 shares worth $207M. The position accounts for 1.19% of the portfolio, ranked #15.

Baker Bros. Advisors first reported a position in EWTX in Q1 2021 and has held it in 21 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Baker Bros. Advisors held 6,575,940 shares of Edgewise Therapeutics worth $207M as of Q1 2026.
  • Baker Bros. Advisors left its Edgewise Therapeutics share count unchanged in Q1 2026.
  • Edgewise Therapeutics made up 1.19% of Baker Bros. Advisors's portfolio in Q1 2026, its #15 holding.
  • Baker Bros. Advisors first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.